![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Novavax Partners With AGC Biologics to Manufacture COVID-19 Vaccine Component
Novavax Partners With AGC Biologics to Manufacture COVID-19 Vaccine Component
![Partner Up, blocks](https://www.fdanews.com/ext/resources/test/Drug-Images4/Partner-Up-blocks.gif?t=1593635821&width=430)
Novavax has partnered with AGC Biologics of Denmark to manufacture an adjuvant for its COVID-19 vaccine candidate NVX-CoV2373.
The adjuvant enhances the immune response to the vaccine and stimulates high levels of neutralizing antibodies to the virus. AGC Biologics will scale up production of the Matrix-M adjuvant to increase Novavax’s capacity to deliver vaccine doses this year.
The Maryland-based company has begun a phase 1/2 trial of NVX‑CoV2373 in Australia and expects to release phase 1 results in July.
Upcoming Events
-
18Jul
-
21Oct